Latest Breaking News On - Urinary symptom profile - Page 1 : comparemela.com

HIFU Proves Noninferior to Radical Prostatectomy in Localized Prostate Cancer

High-intensity focused ultrasound produced noninferior salvage treatment-free survival vs radical prostatectomy in localized prostate cancer.

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

/PRNewswire/ Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease.

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, 2022. Multiple System Atrophy (MSA) is a progressive neurodegenerative disease that presents with motor and prominent autonomic symptoms. Major sources of disability in MSA result from motor symptoms characteristic of Parkinson's disease and impaired ability to maintain normal blood pressure, bowel function and bladder control. Problems with urination are a common symptom experienced in MSA and can occur at any time during the disease process. The poster, entitled, Urinary Symptom Profi

Alterity Therapeutics updates on Multiple System Atrophy study

Alterity Therapeutics (ATHE) Presents Data from bioMUSE Natural History Study